Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q5VVX9
UPID:
UBE2U_HUMAN
Alternative names:
E2 ubiquitin-conjugating enzyme U; Ubiquitin carrier protein U; Ubiquitin-protein ligase U
Alternative UPACC:
Q5VVX9; Q8N1D4
Background:
The Ubiquitin-conjugating enzyme E2 U, also known as E2 ubiquitin-conjugating enzyme U, Ubiquitin carrier protein U, and Ubiquitin-protein ligase U, plays a pivotal role in the ubiquitination pathway. This enzyme is crucial for the covalent attachment of ubiquitin to target proteins, a process fundamental for protein degradation, DNA repair, cell cycle regulation, and signaling.
Therapeutic significance:
Understanding the role of Ubiquitin-conjugating enzyme E2 U could open doors to potential therapeutic strategies. Its central function in ubiquitination highlights its potential as a target for drug discovery, aiming to modulate protein degradation pathways implicated in various diseases.